ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm

New York, NY–(Newsfile Corp. – January 13, 2025) – WHY? The Rosen Law Firm, a global investor protection law firm, is reminding purchasers of AstraZeneca PLC (NASDAQ: LON: ) securities from February 23, 2022 to December 17, 2024, both dates inclusive (the “Class Period”). , February 21, 2025 lead plaintiff deadline In a securities classification application filed for the first time by a company.

SO WHAT? If you purchased AstraZeneca (NASDAQ: ) securities during the Class Period, you may be entitled to a refund without paying any cash fees or expenses through a contingency fee arrangement.

WHAT TO DO NEXT? To join the AstraZeneca course, visit https://rosenlegal.com/submit-form/?case_id=1331 or call Philip Kim, Esq. Toll free at 866-767-3653 or by email at case@rosenlegal.com. A class action lawsuit has already been filed. If you want to act as the main plaintiff, you must move to court no later than February 21, 2025. A lead plaintiff is a representative party acting on behalf of other class members in leading the litigation.

WHY CHOOSE ROSEN LAW? We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, the companies issuing the notices do not have comparable experience, resources or the recognition of any meaningful peers. Many of these firms do not actually handle securities class actions, but are simply brokers who refer clients or are partners with the law firms that actually litigate the cases. The Rosen Law Firm represents investors worldwide, focusing its practice in securities class action and shareholder derivative litigation. ranked number 1 by Action: (WA:) Services for securities class actions in 2017. The company has been ranked in the top 4 every year since 2013. In 2019 alone, the company secured more than 438 million dollars for investors Founding partner Lawrence Rosen was named a titan of plaintiffs’ counsel by law360.Many of the firm’s attorneys have been recognized By Lawdragon and Super Lawyers.

DETAILS OF THE CASE. According to the lawsuit, the defendants made materially false and/or misleading statements throughout the Class Period and/or failed to disclose that: (2) as a result, AstraZeneca faced increased legal exposure in China, which ultimately resulted in AstraZeneca’s China President being arrested by Chinese law enforcement agencies; (3) as a result, AstraZeneca underestimated its legal risks; (4) the foregoing, if disclosed, could materially harm AstraZeneca’s business operations in China; and (5) as a result, the defendants’ statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To join the AstraZeneca course, visit https://rosenlegal.com/submit-form/?case_id=1331 call Philip Kim, Esq. Toll free at 866-767-3653 or by email at case@rosenlegal.com.

No class has been certified. You may not be represented by an attorney. You may also choose to remain an absent class member at this time potential future recovery is not dependent on serving as lead plaintiff.

Follow us for updates on LinkedIn at https://www.linkedin.com/company/the-rosen-law-firm or on Twitter at https://twitter.com/rosen_firm or on Facebook (NASDAQ: ). https:/ /www.facebook.com/rosenlawfirm.

Advertisement of a lawyer. Previous results do not guarantee a similar result.

——————————

To view the original version of this press release, visit https://www.newsfilecorp.com/release/236930